PR
    Pharmacy Remedy

    Immunomodulators

    Revlimid (lenalidomide) in Oman — Regulatory and Supply Information

    Immunomodulatory drug (IMiD) for multiple myeloma (frontline + maintenance + relapsed), myelodysplastic syndrome with 5q- deletion, mantle cell lymphoma and follicular lymphoma. Typical myeloma dose 25 mg on days 1–21 of a 28-day cycle, often combined with dexamethasone (Rd) or dexamethasone + bortezomib (VRd).

    Revlimid (lenalidomide) original manufacturer carton

    Prescription-only medicine. No pricing is published on this page. Prescription-medicine pricing is not advertised to the public in this market.

    This page is informational and is not an advertisement, a promotional communication, or medical advice. It does not offer any medicine for sale to the public. Treatment decisions belong to your treating physician.

    What this medicine is

    Active ingredient
    lenalidomide
    Marketing authorisation holder
    Bristol Myers Squibb / Celgene
    Therapeutic class
    Immunomodulators

    Presentations and dosage forms

    • 5 mg / 10 mg / 15 mg / 20 mg / 25 mg capsules (21 or 28/pack)

    Storage, cold chain and handling

    Store below 30°C in original blister. Handle per REMS-equivalent precautions (teratogenic — see doctor for pregnancy prevention program).

    The regulatory position in Oman

    Medicines in the Sultanate of Oman are regulated by the Ministry of Health, through the Directorate General of Pharmaceutical Affairs and Drug Control. Registration, importation, storage and distribution of pharmaceutical products all fall within that directorate's remit, and every product described on this page is a prescription-only medicine.

    We have not verified Oman's personal-import procedure from a primary source, so we do not describe one. There is no step-by-step process set out on this page and nothing here should be read as an account of what the Ministry requires. Requirements must be confirmed directly with the Ministry of Health before any step is taken.

    What we can describe is the general concept that applies across the region: a named-patient supply. A named-patient supply is a quantity of a prescription medicine intended for one identified patient, requested by that patient's treating physician, documented by a prescription and a medical report, and handled through licensed channels with the cold chain and batch traceability intact. It is not a commercial sale to the public and it is not a substitute for a locally registered product where one is available.

    Assembling the documentation below before approaching the Ministry usually shortens the exchange, whichever route the Directorate General confirms applies to a given product.

    We have not verified Oman's personal-import procedure. We do not describe one here. Confirm the current requirements with the Ministry of Health, Directorate General of Pharmaceutical Affairs and Drug Control.

    Documentation typically required

    • A valid prescription from the treating physician, naming the trade name, active ingredient, concentration and quantity
    • A medical report describing the diagnosis and the treatment plan
    • Proof of identity for the patient
    • Confirmation from the treating clinician of the quantity required for the treatment course
    • For a hospital or clinic: the establishment licence and the request of the responsible pharmacist

    Official sources

    Search terms for this medicine

    The same molecule is searched under several names. All of the following refer to the same product:

    • Revlimid
    • lenalidomide
    • ريفليميد
    • ليناليدوميد
    • Revlimid Oman
    • ريفليميد سلطنة عُمان
    • lenalidomide MOH Oman
    • Revlimid prescription
    • ريفليميد وصفة طبية

    Frequently asked questions

    Prescription-based enquiry

    If you hold a valid prescription from a treating physician in Oman, you can send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing for Oman and we do not sell to the public.

    Send a prescription-based enquiry

    Background reading

    Related medicines

    Medically reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-29 · Ministry of Health — Directorate General of Pharmaceutical Affairs and Drug Control

    For healthcare professionals

    Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.